Cancer treatment method using ailanthone compounds
AssigneeEast China Normal University
InventorsZhengfang Yi, Shihong Peng, Yundong He, Wenbo Zhou, Yihua Chen, Mingyao Liu
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.
Claims10
A method for inhibiting androgen receptor signaling pathway comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula V
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph or co-crystal, to thereby disrupt the interaction of the androgen receptor with its chaperones, and a pharmaceutically acceptable excipient,
- wherein the activity of both full-length androgen receptor (AR-FL) and constitutively active, truncated AR splice variants (AR-Vs) are inhibited, or the androgen receptor (AR) protein level is down-regulated, or the AR protein degradation is induced.
A method for inhibiting the proliferation, metastasis, growth, clone formation of prostate cancer cells, or promoting apoptosis of prostate cancer cells, inducing the cycle arrest of prostate cancer cells in a subject in need thereof, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of ailanthone, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or co-crystal thereof, to disrupt the interaction of androgen receptors with their chaperones, and a pharmaceutically acceptable excipient.
A method for treating prostate cancer comprising administering to a patient an effective amount of a pharmaceutical composition comprising ailanthone, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph or co-crystal thereof, to disrupt the interaction of androgen receptors with their chaperones, and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.